Business Description
Kyowa Kirin Co Ltd
ISIN : US50156R1077
Share Class Description:
KYKOY: ADRTotal Employee Number:
3,503Description
Kyowa Kirin Co Ltd is engaged in research, development, manufacturing, sales, import and export of prescription pharmaceuticals. Its products include KHK4083/AMG 451, rocatinlimab; ziftomenib; OTL-203 KK8398, infigratinib; KHK4951, tivozanib; OTL-201; KK4277; KK2260; KK2269; KK2845; and KK8123.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.84 | |||||
Interest Coverage | 19.05 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 5.47 | |||||
Beneish M-Score | -2.43 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 8.6 | |||||
3-Year EBITDA Growth Rate | 11.3 | |||||
3-Year EPS without NRI Growth Rate | 8.7 | |||||
3-Year FCF Growth Rate | -34.8 | |||||
3-Year Book Growth Rate | 6.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 10.04 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 3.12 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 79.28 | |||||
9-Day RSI | 67.82 | |||||
14-Day RSI | 60.76 | |||||
3-1 Month Momentum % | -11.2 | |||||
6-1 Month Momentum % | -1.22 | |||||
12-1 Month Momentum % | -14.29 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.18 | |||||
Quick Ratio | 2.73 | |||||
Cash Ratio | 1.73 | |||||
Days Inventory | 191.28 | |||||
Days Sales Outstanding | 107.11 | |||||
Days Payable | 307.96 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 2.48 | |||||
Dividend Payout Ratio | 0.44 | |||||
3-Year Dividend Growth Rate | 6.7 | |||||
Forward Dividend Yield % | 2.48 | |||||
5-Year Yield-on-Cost % | 3.54 | |||||
3-Year Average Share Buyback Ratio | 0.9 | |||||
Shareholder Yield % | 2.52 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 73.84 | |||||
Operating Margin % | 21.54 | |||||
Net Margin % | 14.28 | |||||
EBITDA Margin % | 23.87 | |||||
FCF Margin % | 1.41 | |||||
OCF Margin % | 17.77 | |||||
ROE % | 8.47 | |||||
ROA % | 6.83 | |||||
ROIC % | 12.03 | |||||
3-Year ROIIC % | 5.89 | |||||
ROC (Joel Greenblatt) % | 47.27 | |||||
ROCE % | 10.98 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 19.12 | |||||
Forward PE Ratio | 0.11 | |||||
PE Ratio without NRI | 19.12 | |||||
Shiller PE Ratio | 23.47 | |||||
Price-to-Owner-Earnings | 260.62 | |||||
PEG Ratio | 1.61 | |||||
PS Ratio | 2.73 | |||||
PB Ratio | 1.56 | |||||
Price-to-Tangible-Book | 2.7 | |||||
Price-to-Free-Cash-Flow | 258.04 | |||||
Price-to-Operating-Cash-Flow | 15.68 | |||||
EV-to-EBIT | 11.55 | |||||
EV-to-Forward-EBIT | 13.2 | |||||
EV-to-EBITDA | 9.38 | |||||
EV-to-Forward-EBITDA | 10.23 | |||||
EV-to-Revenue | 2.24 | |||||
EV-to-Forward-Revenue | 2.27 | |||||
EV-to-FCF | 211.81 | |||||
Price-to-GF-Value | 0.9 | |||||
Price-to-Projected-FCF | 1.31 | |||||
Price-to-Median-PS-Value | 0.78 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.9 | |||||
Price-to-Graham-Number | 1.52 | |||||
| Price-to-Net-Current-Asset-Value | 4.88 | |||||
| Price-to-Net-Cash | 18.26 | |||||
Earnings Yield (Greenblatt) % | 8.66 | |||||
FCF Yield % | 0.39 | |||||
Forward Rate of Return (Yacktman) % | 12.76 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:KYKOY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Kyowa Kirin Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 3,366.799 | ||
| EPS (TTM) ($) | 0.911 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 26.12 | ||
| 14-Day RSI | 60.76 | ||
| 14-Day ATR ($) | 0.246837 | ||
| 20-Day SMA ($) | 15.27883 | ||
| 12-1 Month Momentum % | -14.29 | ||
| 52-Week Range ($) | 14.285 - 18.66 | ||
| Shares Outstanding (Mil) | 523.49 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Kyowa Kirin Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Kyowa Kirin Co Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| USD 0.201524 Cash Dividend | 2025-12-31 | 14.48 (+0.00%) | ||
| USD 0.201342 Cash Dividend | 2025-06-30 | 16.69 (+0.00%) | ||
| USD 0.194539 Cash Dividend | 2024-12-31 | 15.72 (+0.00%) |
Show
Entries
Kyowa Kirin Co Ltd Frequently Asked Questions
What is Kyowa Kirin Co Ltd(KYKOY)'s stock price today?
The current price of KYKOY is $16.25. The 52 week high of KYKOY is $18.66 and 52 week low is $14.29.
When is next earnings date of Kyowa Kirin Co Ltd(KYKOY)?
The next earnings date of Kyowa Kirin Co Ltd(KYKOY) is .
Does Kyowa Kirin Co Ltd(KYKOY) pay dividends? If so, how much?
The Dividend Yield % of Kyowa Kirin Co Ltd(KYKOY) is 2.48% (As of Today), Highest Dividend Payout Ratio of Kyowa Kirin Co Ltd(KYKOY) was 0.6. The lowest was 0.35. And the median was 0.48. The Forward Dividend Yield % of Kyowa Kirin Co Ltd(KYKOY) is 2.48%. For more information regarding to dividend, please check our Dividend Page.
Guru Commentaries on OTCPK:KYKOY
No articles.
Press Release
Articles on Kyowa Kirin Co Ltd
No articles.
Headlines
See More- 1
Jun 29, 2026
Eli Lilly, Regeneron named to FDA pilot program to boost US drug manufacturing
Seeking Alpha • 4:50pm
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers